Affimed (AFMD) - P/S ratio

P/S ratio as of November 2026 (TTM): 3.09

According to Affimed 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.1554. At the end of 2023 the company had a P/S ratio of 10.4.

P/S ratio history for Affimed from 2014 to 2023

PS ratio at the end of each year

Year	P/S ratio	Change
2023	10.4	142.77%
2022	4.29	-69.51%
2021	14.1	-17.84%
2020	17.1	96.78%
2019	8.71	22%
2018	7.14	-71.46%
2017	25.0	192.04%
2016	8.56	-69.84%
2015	28.4	-15.44%
2014	33.6

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Repligen RGEN	14.1	356.64%	🇺🇸 USA
Merrimack Pharmaceuticals MACK	N/A	N/A	🇺🇸 USA
Agenus AGEN	2.44	-21.19%	🇺🇸 USA
Acorda Therapeutics ACOR	0.0071	-99.77%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Affimed (AFMD)

P/S ratio as of November 2026 (TTM): 3.09